Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment

BACKGROUND: A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC have yet to show efficacy in clinical trials. These findings raise question about the ability of standard HER2 diagnostics to acc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: An, E., Ock, C.-Y., Kim, T.-Y., Lee, K.-H., Han, S.-W., Im, S.-A., Liao, W.-L., Cecchi, F., Blackler, A., Thyparambil, S., Kim, W. H., Burrows, J., Hembrough, T., Catenacci, D. V. T., Oh, D.-Y., Bang, Y.-J.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5378223/
https://ncbi.nlm.nih.gov/pubmed/27687309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw442
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados